- $209.29m
- $144.98m
- $83.79m
- 45
- 28
- 87
- 53
Annual income statement for Pulmonx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 32.7 | 48.4 | 53.7 | 68.7 | 83.8 |
| Cost of Revenue | |||||
| Gross Profit | 21.2 | 35.6 | 39.9 | 50.8 | 62 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 65.1 | 95.7 | 112 | 131 | 141 |
| Operating Profit | -32.3 | -47.3 | -58.6 | -61.9 | -57.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -32 | -48.3 | -58.6 | -60.3 | -55.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -32.2 | -48.7 | -58.9 | -60.8 | -56.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -32.2 | -48.7 | -58.9 | -60.8 | -56.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -32.2 | -48.7 | -58.9 | -60.8 | -56.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.903 | -1.35 | -1.59 | -1.6 | -1.41 |